Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2019-05-20 Director's Dealing
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-05-20 English
FORM 4/A
Director's Dealing
2019-05-20 English
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 1, 2019, reporting the company's financial and operating results for the quarter ended March 31, 2019. It includes a press release as an exhibit announcing these results. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not deemed "filed" for certain regulatory purposes. The document is short (3381 characters) and primarily serves as an announcement of the earnings release rather than the full financial report itself. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only, rather than a full Interim/Quarterly Report (IR) which would contain substantive financial data and analysis. Hence, the correct classification is ER with high confidence.
2019-05-01 English
10-Q
Interim / Quarterly Report Q1 2019
2019-05-01 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-05 English
Regulatory Filings 2019
Regulatory Filings
2019-03-18 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.